{"analyses":[{"ciLowerLimit":"-0.0452","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.1029","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.0001","paramType":"Slope","paramValue":"0.0741","statisticalComment":"degrees of freedom: 4505","statisticalMethod":"ANOVA","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"2.4","value":"4.6"},{"groupId":"OG001","spread":"2.2","value":"5.0"},{"groupId":"OG002","spread":"2.4","value":"5.3"}]}]}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"638"},{"groupId":"OG002","value":"635"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"541"},{"groupId":"OG001","value":"2513"},{"groupId":"OG002","value":"2875"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","dispersionType":"Standard Deviation","groups":[{"description":"Cancer patients treated with chemotherapy with low toxicity (\\<10% risk) and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: <10% Risk"},{"description":"Cancer patients treated with chemotherapy with medium toxicity (10-20% risk) and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: 10-20% Risk"},{"description":"Cancer patients treated with chemotherapy with high toxicity (\\>20% risk) and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG002","title":"EP2006: >20% Risk"}],"paramType":"MEAN","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Duration by Chemotherapy Toxicity: Cycle Level","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"days"}